TwinBeech Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

TwinBeech Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$355K	Sell	16,954 -83,198	-83%	-$1.87M	0.04%	417
2025 Q4	$2.3M	Buy	+100,152	New	+$3.29M	0.16%	171
2025 Q3	–	Sell	-10,789	Closed	-$392K	–	784
2025 Q2	$392K	Sell	10,789 -84,615	-89%	-$3.05M	0.01%	523
2025 Q1	$3.45M	Buy	95,404 +61,547	+182%	+$2.56M	0.06%	306
2024 Q4	$1.42M	Buy	33,857 +28,497	+532%	+$1.41M	0.02%	354
2024 Q3	$298K	Sell	5,360 -12,453	-70%	-$634K	0.01%	617
2024 Q2	$732K	Buy	+17,813	New	+$761K	0.01%	425
2022 Q4	–	Sell	-110,066	Closed	-$4.56M	–	894
2022 Q3	$4.56M	Buy	+110,066	New	+$5.66M	0.12%	205
2021 Q3	–	Sell	-17,927	Closed	-$1.71M	–	724
2021 Q2	$1.71M	Buy	+17,927	New	+$1.87M	0.21%	147
2021 Q1	–	Sell	-6,830	Closed	-$945K	–	639
2020 Q4	$945K	Buy	+6,830	New	+$810K	0.15%	184

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

TwinBeech Capital's RARE Position: Q1 2026 in Review

TwinBeech Capital reduced its Ultragenyx Pharmaceutical (RARE) stake by 83% in Q1 2026, selling an estimated $1.87M and leaving 16,954 shares worth $355K. The position accounts for 0.04% of the portfolio, ranked #417.

TwinBeech Capital first reported a position in RARE in Q4 2020 and has held it in 10 quarters since. The position peaked at $4.56M in Q3 2022. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

TwinBeech Capital held 16,954 shares of Ultragenyx Pharmaceutical worth $355K as of Q1 2026.
TwinBeech Capital sold 83,198 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.87M.
Ultragenyx Pharmaceutical made up 0.04% of TwinBeech Capital's portfolio in Q1 2026, its #417 holding.
TwinBeech Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 10 quarters since.
TwinBeech Capital's Ultragenyx Pharmaceutical position peaked at $4.56M in Q3 2022.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.